T. Rowe Price Associates
AIMT

T. Rowe Price Associates’s Aimmune Therapeutics AIMT Stock Holding History

T. Rowe Price Associates’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,274,902
Closed -$88.1M – 2651
2020
Q2 		$88.1M Buy
5,274,902
+82,229
+2% +$1.4M 0.01% 669
2020
Q1 		$74.9M Sell
5,192,673
-429,865
-8% -$11M 0.01% 658
2019
Q4 		$188M Buy
5,622,538
+310,054
+6% +$8.67M 0.02% 493
2019
Q3 		$111M Buy
5,312,484
+65,880
+1% +$1.34M 0.02% 606
2019
Q2 		$109M Buy
5,246,604
+535,072
+11% +$11M 0.02% 623
2019
Q1 		$105M Sell
4,711,532
-60,377
-1% -$1.42M 0.02% 626
2018
Q4 		$114M Buy
4,771,909
+86,452
+2% +$2.24M 0.02% 571
2018
Q3 		$128M Buy
4,685,457
+31,516
+0.7% +$891K 0.02% 604
2018
Q2 		$125M Buy
4,653,941
+161,864
+4% +$4.95M 0.02% 598
2018
Q1 		$143M Buy
4,492,077
+1,977,910
+79% +$69.6M 0.02% 552
2017
Q4 		$95.1M Buy
2,514,167
+1,136,368
+82% +$36.7M 0.02% 664
2017
Q3 		$34.2M Sell
1,377,799
-18,600
-1% -$401K 0.01% 1001
2017
Q2 		$28.7M Buy
1,396,399
+227,627
+19% +$4.34M 0.01% 1036
2017
Q1 		$25.4M Buy
1,168,772
+82,621
+8% +$1.69M ﹤0.01% 1060
2016
Q4 		$22.2M Sell
1,086,151
-76,379
-7% -$1.56M ﹤0.01% 1104
2016
Q3 		$17.4M Buy
1,162,530
+558,432
+92% +$7.54M ﹤0.01% 1182
2016
Q2 		$6.54M Buy
604,098
+115,700
+24% +$1.57M ﹤0.01% 1360
2016
Q1 		$6.62M Sell
488,398
-2,050
-0.4% -$32K ﹤0.01% 1343
2015
Q4 		$9.05M Buy
490,448
+48,810
+11% +$903K ﹤0.01% 1306
2015
Q3 		$11.2M Buy
+441,638
New +$10.3M ﹤0.01% 1287

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates's AIMT Position: Q3 2020 in Review

T. Rowe Price Associates sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 5,274,902 shares — an estimated $88.1M sold.

T. Rowe Price Associates first reported a position in AIMT in Q3 2015 and held it in 20 quarters. The position peaked at $188M in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • T. Rowe Price Associates reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 5,274,902 Aimmune Therapeutics shares in Q3 2020, an estimated $88.1M.
  • T. Rowe Price Associates first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 20 quarters.
  • T. Rowe Price Associates's Aimmune Therapeutics position peaked at $188M in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on T. Rowe Price Associates's 13F filing for Q3 2020, filed 16 Nov 2020.